Study S000718

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without Metformin

ClinicalTrials.gov record

Registration

Registration: NCT06323161
Acronym: REIMAGINE 3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 274
Start: 2024-03-26
Primary completion: 2025-09-09
Lead sponsor: Novo Nordisk A/S
Conditions: Type 2 Diabetes
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1283-0754; OTHER:2022-502679-43

Registered primary outcomes

Change in Glycated Haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 40)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004786	Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Rosenstock J, Lancet (London, England)	2026	Randomized trial	PMID 42251856 DOI	cites ClinicalTrials.gov:NCT06323161; registry reference DERIVED:42251856